Elevated CA 19-9 levels in a patient with mirizzi syndrome: Case report

Southern Medical Journal

Volumn 99, Issue 2, 2006, Pages 160-163

  Sanchez, Mayra ^a   Gomes, Hilton ^a   Marcus, Erin N ^a  

^a JACKSON MEMORIAL HOSPITAL   (United States)

Author keywords

CA 19 9; Cholangiocarcinoma; Choledocholithiasis; Mirizzi syndrome

Indexed keywords

ANTIBIOTIC AGENT; CA 19-9 ANTIGEN; BIOLOGICAL MARKER;

ADULT; ANTIBIOTIC THERAPY; ANTIGEN DETECTION; ARTICLE; BILE DUCT CARCINOMA; BILE DUCT OBSTRUCTION; CASE REPORT; CHOLELITHIASIS; CLINICAL FEATURE; COMMON BILE DUCT STONE; DIFFERENTIAL DIAGNOSIS; DISEASE MARKER; ECHOGRAPHY; ENDOSCOPIC RETROGRADE CHOLANGIOPANCREATOGRAPHY; FATTY LIVER; GALLSTONE; HEPATIC DUCT; HUMAN; LABORATORY TEST; LAPAROTOMY; LIVER BIOPSY; MALE; MIRIZZI SYNDROME; PHYSICAL EXAMINATION; BLOOD; COMPUTER ASSISTED TOMOGRAPHY; GALLBLADDER TUMOR; MIDDLE AGED; NEEDLE BIOPSY; NUCLEAR MAGNETIC RESONANCE IMAGING; OBSTRUCTIVE JAUNDICE; SYNDROME;

BIOLOGICAL MARKERS; BIOPSY, NEEDLE; CA-19-9 ANTIGEN; CHOLANGIOCARCINOMA; CHOLEDOCHOLITHIASIS; CHOLESTASIS, EXTRAHEPATIC; DIAGNOSIS, DIFFERENTIAL; GALLBLADDER NEOPLASMS; HUMANS; JAUNDICE, OBSTRUCTIVE; LAPAROTOMY; MAGNETIC RESONANCE IMAGING; MALE; MIDDLE AGED; SYNDROME; TOMOGRAPHY, X-RAY COMPUTED;

EID: 33644972079     PISSN: 00384348     EISSN: None     Source Type: Journal    
DOI: 10.1097/01.smj.0000198465.21994.19     Document Type: Article

References (25)

1. Mirizzi PL. Sindrome del conducto hepatico. J Int Chir 1948;8:731-737.
2. Csendes A, Diaz JC, Burdiles P, et al. Mirrizzi Syndrome and cholcystobiliary fistula: a unifying classification. Br J Surg 1989;76:1139-1143.
3. Pemberton M, Wells AD. The Mirizzi syndrome. Postgrad Med J 1997;73:487-490.
4. McSherry CK, Ferstenberg H, Virshup M. The Mirizzi syndrome: Suggested classification and surgical therapy. Surg. Gastroenterol 1982;1:219-225.
5. Nagakawa T, Ohta T, Kayahara M, et al. A new classification of Mirizzi syndrome from diagnostic and therapeutic viewpoints. Hepatogastroenterology 1997;44:63-7.
6. Chan CY, Liau KH, Ho CK, et al. Mirizzi Syndrome: a diagnostic and operative challenge. Surg Journal of the Royal Colleges of Surgeons of Edinburgh and Ireland 2003;1:273-278.
7. Tan KY, Chng HC, Chen CY, et al. Mirizzi syndrome: noteworthy aspects of a retrospective study in one center. ANZ J Surg 2004;74:833-837.
8. Abou-Saif A, Al-Kawas FH. Complications of gallstone disease: Mirizzi syndrome, cholecystocholedochal fistula, and gallstone ileus. Am J Gastroenterology 2002;97:149-254.
9. Curet MN, Rosendale DE, Congilosi S. Mirizzi syndrome in a Native American Population. Am J Surg 1994;168:616-621.
10. Atkinson BF, Ernst C, Herlyn M, et al. Gastrointestinal cancer associated antigen in immunoperoxidase assay. Cancer Res 1982;42:4820-4823.
11. Arends JW, Verstynen C, Bosman FT, et al. Distribution of monoclonal antibody-defined monosialoganglioside in normal and cancerous human tissues: an immunoperoxidase study. Hybridoma 1983;2:219-229.
12. Perkins GL, Slater ED, Sanders GK, et al. Serum tumor markers. Am Fam Physician 2003;68:1075-1088.
13. Mann DV, Edwards R, Ho S, et al. Elevated tumour marker CA 19-9: clinical interpretation and influence of obstructive jaundice. Eur Jour of Sur Onc 2000;26:474-479.
14. Pavai S, Yap SF. The clinical significance of elevated levels of serum CA 19-9. Med J Malaysia. 2003;58:667-72.
15. Fan ST, Lan WY, Lee MJR, et al. Cholecysto-hepaticodochal fistula, the value of pre-operative recognition. Br J Surg 1985;72:743-744.
16. Ng WW, Tong KJ, Tam TN, et al. Clinical values of CA 19-9, CA 125 and CEA in malignant obstructive jaundice. Zhonghua Yi Xue Za Zhi 1995;55:438-446.
17. Peterli R, Meyer-Wyss B, Herzog U, et al. CA 19-9 has no value as a tumor marker in obstructive jaundice. Schweiz Med Wochenschr 199; 129:77-79.
18. Magnani J, Steplewski Z, Koprowski H, et al. Identification of the gastrointestinal and pancreatic cancer associated antigen detected by monoclonal antibody 19-9 in the sera of patients as a mucin. Cancer Res 1983;43:5489-5492.
19. McFarlane IG. Hepatic clearance of serum glycoproteins. Clin Sci 1983;64:127-135.
20. Kim PN, Outwater EK, Mitchell DG. Mirizzi syndrome: evaluation by MR imaging. Am J Gastroenterol 1999;94:2546-2550.
21. Becker CD, Hassler H, Terrier F. Preoperative diagnosis of the Mirizzi syndrome: limitations of sonography and computed tomography. American Journal of Roentgen 1984;143:591-596.
22. Dewar G, Chung SC, Li AK. Operative strategy in the Mirizzi syndrome. Surg Gynecol Obstet 1990;171:157-159.
23. Berland LL, Lawson TL, Stanley RJ. CT appearance of Mirizzi syndrome. J Comput Assist Tomogr 1984;8:165-166.
24. Choi BW, Kim MJ, Chung JJ, et al. Radiologie findings of Mirizzi syndrome with emphasis on MRI. Yonsei Medical Journal 2000;41:144-146.
25. Yip AWC, NG WS, Suen WS, et al. Type II Mirizzi syndrome: diagnosis by endoscopic retrograde cholangiopancreatography. JR Coll Surg Edin 1992;37:49-55.